PLoS ONE (Jan 2022)

DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling

  • Stephanie S. Kim,
  • Ina Kycia,
  • Michael Karski,
  • Rosanna K. Ma,
  • Evan A. Bordt,
  • Julian Kwan,
  • Anju Karki,
  • Elle Winter,
  • Ranan G. Aktas,
  • Yuxuan Wu,
  • Andrew Emili,
  • Daniel E. Bauer,
  • Praveen Sethupathy,
  • Khashayar Vakili

Journal volume & issue
Vol. 17, no. 2

Abstract

Read online

Fibrolamellar carcinoma (FLC) is a primary liver cancer that most commonly arises in adolescents and young adults in a background of normal liver tissue and has a poor prognosis due to lack of effective chemotherapeutic agents. The DNAJB1-PRKACA gene fusion (DP) has been reported in the majority of FLC tumors; however, its oncogenic mechanisms remain unclear. Given the paucity of cellular models, in particular FLC tumor cell lines, we hypothesized that engineering the DP fusion gene in HEK293T cells would provide insight into the cellular effects of the fusion gene. We used CRISPR/Cas9 to engineer HEK293T clones expressing DP fusion gene (HEK-DP) and performed transcriptomic, proteomic, and mitochondrial studies to characterize this cellular model. Proteomic analysis of DP interacting partners identified mitochondrial proteins as well as proteins in other subcellular compartments. HEK-DP cells demonstrated significantly elevated mitochondrial fission, which suggests a role for DP in altering mitochondrial dynamics. Transcriptomic analysis of HEK-DP cells revealed a significant increase in LINC00473 expression, similar to what has been observed in primary FLC samples. LINC00473 overexpression was reversible with siRNA targeting of PRKACA as well as pharmacologic targeting of PKA and Hsp40 in HEK-DP cells. Therefore, our model suggests that LINC00473 is a candidate marker for DP activity.